Chapter Update Summary

4/9/2019

4/9/2019

10/1/2018

10/1/2018

8/20/2018

8/20/2018

8/20/2018

8/20/2018

3/1/2018

10/18/2016

1/27/2016

7/6/2015

3/19/2015

11/17/2014

9/12/2014

8/8/2014

7/9/2014

1/27/2014

12/11/2013

10/24/2013

9/4/2013

9/26/2012

4/11/2012

11/1/2011

6/6/2011

3/4/2011

12/7/2010

  • Updated to reflect the 2010 IAS-USA antiretroviral guidelines
  • Updated to reflect the discontinuation of development of vicriviroc, bevirimat, apricitabine
  • Updated to include preliminary information on phenotypic tropism testing of HIV proviral DNA from peripheral blood mononuclear cells

8/27/2010

  • Updated with results of the phase III ECHO and THRIVE studies comparing rilpivirine vs efavirenz in treatment-naive patients
  • Updated with manufacturer withdrawal of vicriviroc from further development

4/13/2010

  • Updated to include an FDA safety warning about saquinavir/ritonavir
  • Updated information of the use of vicriviroc in treatment-experienced patients

12/17/2009

  • Updated to reflect December 2009 DHHS guideline revision and expanded indication for maraviroc.